文献速递临床试验与 GCP真实世界研究与卫生经济流行病学与生物统计

Food 4 Health - He Oranga Kai:评估鼠李糖乳杆菌HN001与β-葡聚糖改善糖尿病前期成人糖化血红蛋白、代谢健康及整体福祉的疗效、可接受性与经济影响:一项2×2析因设计、平行组、安慰剂对照随机对照试验的研究方案,含嵌入式定性研究与经济学分析

Food 4 Health - He Oranga Kai: Assessing the efficacy, acceptability and economic implications of Lactobacillus rhamnosus HN001 and β-glucan to improve glycated haemoglobin, metabolic health, and general well-being in adults with pre-diabetes: study protocol for a 2 × 2 factorial design, parallel group, placebo-controlled randomized controlled trial, with embedded qualitative study and economic an
PubMed 文献 · Trials · 2019-07-29

该研究为2×2析因设计、随机、平行组、安慰剂对照试验,计划纳入152名18-80岁糖尿病前期成人(糖化血红蛋白41-49 mmol/mol),评估鼠李糖乳杆菌HN001胶囊(每日6×10^9 CFU)与含4 g β-葡聚糖谷物干预6个月对糖化血红蛋白等代谢及心理健康指标的效果,并嵌入定性研究与经济学模拟分析。

要点

  • 研究纳入糖化血红蛋白41-49 mmol/mol的糖尿病前期成人,干预6个月,随访至9个月评估应答持久性。
  • 主要结局为6个月时糖化血红蛋白;次要结局包括3和9个月糖化血红蛋白、空腹血糖、胰岛素抵抗、血压、体重、BMI及血脂。
  • 嵌入式定性研究在2个月时对β-葡聚糖组24人进行半结构化访谈,6个月时开展参与者焦点小组及三个卫生专业人员焦点小组。

核心结论

  • 该研究将评估益生菌胶囊与益生元谷物干预在糖尿病前期人群中的疗效,定性部分提供对干预看法的丰富描述,结合经济学分析为将干预转化为实践提供见解。

研究设计与样本

  • 2×2析因设计、随机、平行组、安慰剂对照试验,计划纳入152名18-80岁糖尿病前期成人(糖化血红蛋白41-49 mmol/mol)。
  • 采用计算机生成的区组随机化,由独立方执行;干预分组为AB、AO1、BO2、O1O2,干预6个月,随访至9个月。
  • 结局评估者对胶囊分配设盲;嵌入式定性研究包括24次面对面半结构化访谈、参与者焦点小组及三个卫生专业人员焦点小组;并采用模拟模型估算质量调整生命年与卫生系统成本。

主要发现

  • 原文为研究方案,未报告结果。

关键数值与推荐

  • 干预A为鼠李糖乳杆菌HN001胶囊(每日6×10^9菌落形成单位);干预B为含4 g β-葡聚糖的谷物;O1为安慰剂胶囊;O2为热量匹配的对照谷物。
  • 主要结局为6个月时糖化血红蛋白;次要结局包括3和9个月糖化血红蛋白、空腹血糖、胰岛素抵抗、血压、体重、体质指数及血脂水平。
  • 整体福祉与生活质量采用简明健康调查量表36(SF-36)和抑郁焦虑压力量表21(DASS-21)在6和9个月时测量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The rates of pre-diabetes and type 2 diabetes mellitus are increasing worldwide, producing significant burdens for individuals, families, and healthcare systems. In New Zealand, type 2 diabetes mellitus and pre-diabetes disproportionally affect Māori, Pacific, and South Asian peoples. This research evaluates the efficacy, acceptability, and economic impact of a probiotic capsule and a prebiotic cereal intervention in adults with pre-diabetes on metabolic and mental health and well-being outcomes. METHODS: Eligible adults (n = 152) aged 18-80 years with pre-diabetes (glycated haemoglobin 41-49 mmol/mol) will be enrolled in a 2 × 2 factorial design, randomised, parallel-group, placebo-controlled trial. Computer-generated block randomization will be performed independently. Interventions are capsulated Lactobacillus rhamnosus HN001 (6 × 109 colony-forming units/day) (A) and cereal containing 4 g β-glucan (B), placebo capsules (O1), and calorie-matched control cereal (O2). Eligible participants will receive 6 months intervention in the following groups: AB, AO1, BO2, and O1O2. The primary outcome is glycated haemoglobin after 6 months. Follow-up at 9 months will assess the durability of response. Secondary outcomes are glycated haemoglobin after 3 and 9 months, fasting glucose, insulin resistance, blood pressure, body weight, body mass index, and blood lipid levels. General well-being and quality of life will be measured by the Short-Form Health Survey 36 and Depression Anxiety Stress Scale 21 at 6 and 9 months. Outcome assessors will be blind to capsule allocation. An accompanying qualitative study will include 24 face-to-face semistructured interviews with an ethnically balanced sample from the β-glucan arms at 2 months, participant focus groups at 6 months, and three health professional focus groups. These will explore how interventions are adopted, their acceptability, and elicit factors that may support the uptake of interventions. A simulation model of the pre-diabetic New Zealand population will be used to estimate the likely impact in quality-adjusted life years and health system costs of the interventions if rolled out in New Zealand. DISCUSSION: This study will examine the efficacy of interventions in a population with pre-diabetes. Qualitative components provide rich description of views on the interventions. When combined with the economic analysis, the study will provide insights into how to translate the interventions into practice. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12617000990325. Prospectively registered on 10 July 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Barthow C, Hood F, McKinlay E, et al. Food 4 Health - He Oranga Kai: Assessing the efficacy, acceptability and economic implications of Lactobacillus rhamnosus HN001 and β-glucan to improve glycated haemoglobin, metabolic health, and general well-being in adults with pre-diabetes: study protocol for a 2 × 2 factorial design, parallel group, placebo-controlled randomized controlled trial, with embedded qualitative study and economic analysis. Trials. 2019. PMID: 31358022. doi:10.1186/s13063-019-3553-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。